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Résumé 
Estimer la filtration glomérulaire chez les personnes âgées, tout en tenant compte de la difficulté 
supplémentaire d'évaluer leur masse musculaire, est difficile et particulièrement important pour la 
pres.cription de médicaments. Le taux plasmatique de la créatinine dépend à la fois de la fraction 
d'élimination rénale et extra-rénale et de la masse musculaire. Actuellement, pour estimer la 
filtration glomérulaire différentes formules sont utilisées, qui se fondent principalement sur la valeur 
de la créatinine. Néanmoins, en raison de la fraction éliminée par les voies tubulaires et 
intestinales la clairance de la créatinine surestime généralement le taux de filtration glomérulaire 
(GFR). 
Le but de cette étude est de vérifier la fiabilité de certains marqueurs et algorithmes de la fonction 
rénale actuellement utilisés et d'évaluer l'avantage additionnel de prendre en considération la 
masse musculaire mesurée par la bio-impédance dans une population âgée(> 70 ans) et avec 
une fonction rénale chronique compromise basée sur MORD eGFR (CKO stades llF-IV). Dans cette 
étude nous comparons 5 équations développées pour estimer la fonction rénale et basées 
' . 
respectivement sur la créatinine sérique (Cockcroft et MORD), la cystatine C (Larsson), la 
créatinine combinée à la bêta-trace protéine (White), et la créatinine ajustée à la masse musculaire 
obtenue par analyse de la bio-impédance (MacDonald). La bio-impédance est une méthode 
couramment ufüisée pour estimer la composition corporelle basée sur l'étude des propriétés 
· électriques passives et de la géométrie des tissus biologiques. Cela permet d'estimer les volumes 
relatifs des différents tissus ou des fluides dans le corps, comme par exemple l'eau corporelle 
totale, la masse musculaire (=masse maigre) et la masse grasse corporelle. 
Nous avons évalué, dans une population âgée d'un service interne, et en utilisant la clairance de 
l'inuline (single shot) comme le « gold standard », les algorithmes de Cockcroft (GFR CKC), 
MORD, Larsson (cystatine C, GFR CYS), White (beta trace protein, GFR BTP) et Macdonald (GFR 
= ALM, la masse musculaire par bio-impédance. 
Lés résultats ont montré que le GFR (mean ± SO) mesurée avec l'inuline et calculée avec les 
algorithmes étaient respectivement de: 34.9±20 ml/min pour l'inuline, 46.7±18.5 ml/min pour c·KC, 
47.2±23 · ml/min pour CYS, 54.4±18.2ml/min pour BTP, 49±15.9 ml/min pour MORD et 
32.9±27.2ml/min pour ALM. Les courbes ROC comparant la sensibilité et la spécificité, l'aire sous 
la courbe (AUC) et l'intervalle de confiance 95% étaient respectivement de : CKC 0.68 (055-0.81 ), 
MORD 0.76 (0.64-0.87), Cystatin C 0.82 (0.72-0.92), BTP 0.75 (0.63-0.87), ALM 0.65 (0.52-0.78). 
En conclusion, les algorithmes comparés dans cette étude surestiment la GFR dans la population 
âgée et hospitalisée, avec des polymorbidités et une classe CKD Ill-IV. L'utilisation de l'impédance 
bioélectrique pour réduire l'erreur de l'estimation du GFR basé sur la créatinine n'a fourni aucune 
contribution significative, au contraire, elle a montré de moins bons résultats en comparaison aux 
~utres équations. En fait dans cette étude 75% des patients ont changé leur classification CKD 
avec MacDonald (créatinine et masse musculaire), contre 49% avec CYS (cystatine C), 56% avec 
MORD, 52% avec Cockcroft et 65% avec BTP. Les meilleurs résultats ont été obtenus avec 
Larsson (CYS C) et la formule de Cockcroft.· 
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Summary 
QUESTIONS UNDER STUDY AND PRINCIPLES: Es-
timating glomerular filtration rate (GFR) in hospitalised 
patients with chronic kidney disease (CKD) is important 
for drug prescription but it remains a difficult task. The pur-
pose of this study was to investigate the reliability of se-
lected algorithms based on serum creatinine, cystatin C and 
beta-trace protein to estimate GFR and the potential added 
advantage ofmeasuring muscle mass by bioimpedance. 
METHODS: In a prospective unselected group of patients 
hospitalised in a general internai medicine ward with CKD, 
GFR was evaluated using inulin clearance as the gold 
standard and the algorithms of Cockcroft, MDRD, Larsson 
(cystatin C), White (beta-trace) and MacDonald (creatinine 
and muscle mass by bioimpedance). 
RESULTS: 69 patients were included in the study. Median 
age (interquartile range) was 80 years (73-83); weight 74.7 
kg (67.0-85.6), appendicular Jean mass 19.1 kg 
(14.9-22.3), serum creatinine 126 µmol/! (100-149), 
cystatin C 1.45 mg/l (1.19-1.90), beta-trace protein 1.17 
mg/! (0.99-1.53) and GFR measured by inulin 30.9 ml/ 
min (22.0-43.3). The errors in the estimation of GFR and 
the area under the ROC curves (95% confidence interval) 
relative to inulin were respectively: Cockcroft 14.3 ml/ 
min (5.55-23.2) and 0.68 (0.55-0.81), MDRD 16.3 ml/ 
min (6.4--27.5) and 0.76 (0.64--0.87), Larsson 12.8 ml/min 
(4.50-25.3) and 0.82 (0.72-0.92), White 17.6 ml/min 
(11.5-31.5) and 0.75 (0.63-0.87), MacDonald 32.2 ml/min 
(13.9--45.4) and 0.65 (0.52-0.78). 
CONCLUSIONS: Currently used algorithms overestimate 
GFR in hospitalised patients with CKD. As a consequence 
eGFR targeted prescriptions of renal-cleared drugs, might 
expose patients to overdosing. The best results were ob-
tained with the Larsson algorithm. The determination of 
muscle mass by bioimpedance did not provide significant 
contributions. 
Key words: glomerularjiltration rate; eGFR; estimation; 
bioimpedance; inulin clearance; cystatin C; be/a-trace 
protein; inpatients 
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Introduction 
Glomerular filtration rate (GFR) can be measured using 
standardised methods such as the determination of inulin 
clearance or by calculating the clearance of alternative sub-
strates, such as iodinated contrast agents (for instance, io-
hexol) or radioisotopes [ I ]. In clinical practice, however, 
determination of GFR by these methods is so cumbersome 
and costly that clinicians cannot use them on a regular basis 
and must be satisfied with an estimation of GFR calcu-
lated from endogenous markers of kidney function, tradi-
tionally serum creatinine and, more recently, cystatin C and 
beta-trace protein. The determination of creatinine is re-
producible, not expensive and easily accessible. However, 
the use of creatinine for measuring kidney function bas a 
number of limitations, specifically owing to the fraction of 
the substance eliminated by non-renal routes and to its de-
pendence on muscle mass and, last but not least, on diet-
ary intake [2-11]. Cystatin C and beta-trace protein do of-
fer some theoretical advantages, the main one being their 
low susceptibility to anthropometric variables [ 2-20]; 
however, they have failed to win a place in the delicate 
compromise between determination cost, accuracy and re-
producibility despite the fact that they have now been avail-
able for a number ofyears [2 l-24]. Also owing to limited 
intra-individual variability, creatinine thus continues to be 
the endogenous substrate of first choice for estimating kid-
ney function and, when appropriate, for determining the 
stage of dysfonction [25, 26]. 
Starting from creatinine it is possible to estimate either, 
GFR by a number of formulas, the most popular of which 
is the one obtained by Levey in 1999 from the Modification 
of Diet in Rena! Disease (MDRD) study data [ 4, 5] or cre-
atinine clearance with the equation published by Cockcroft 
in 1976 [3]. Because of the fraction eliminated by tubu-
lar and intestinal routes, creatinine clearance usually over-
estimates GFR; however, the difference between the two 
measurements falls within determination-related error dis-
persion [27]. For the purpose of correcting the error given 
by the difference between individual muscle mass and av-
erage muscle mass by age group [28, 29], MacDonald pro-
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posed in 2006 an equation that also included determination 
of appendicular Jean mass by bioelectrical impedance ana-
lysis [.10, 31]. 
There are also dedicated equations available for estimating 
GFR from cystatin C and beta-trace protein (proposed by 
Larsson in 2004 [ 13] and by White in 2007, respectively 
[20]), that are not or little affected by body composition 
[ l 2-20] but are unfortunately exposed to great intra- and 
inter-individual variability just like the substrates they are 
based on [21-24]. 
Despite progress in knowledge about endogenous markers 
ofkidney function, the determination ofGFR remains diffi-
cult. The difficulty is forther enhanced in patients at the ex-
tremes of the normal distribution, particularly with regard 
to weight, muscle mass, and age [2, 7, 32]. 
The frai! elderly who are admitted to internai medicine 
wards, with their many comorbidities and the consequences 
of their disabilities, often have complex conditions treated 
with medications having a narrow therapeutic spectrum 
and, by definition, they put the equations used for estim-
ating kidney fonction to the hardest of tests. This is even 
more so when we know that one third to one fourth of ail 
patients above 60 years of age, some of whom with normal 
creatinine values, have at least stage III chronic kidney dis-
ease (CKD) [33] and that GFR has been shown to decrease 
by 0.8 ml/min/year on average, starting from the age of 40 
[2]. 
Confosed by the number and diversity of available equa-
tions, and anxious to verify their accuracy in the elderly 
population of our internai medicine wards with CKD and 
moderately compromised kidney fonction, we decided to 
compare the main equations (Cockcroft [3], MDRD [5], 
White [20], Larsson [ 13] and MacDonald [30]), using in-
ulin clearance as the gold standard [34, 35]. 
Materials and methods 
Patients and measurements 
We recruited 70 unselected Caucasian patients with CKD 
and moderate kidney fonction impairment (stage III-IV ac-
cording to KDOQI guidelines [25]) among the elderly pop-
ulation (>70 year old) of the internai medicine wards oftwo 
secondary carc hospitals in the south of Switzerland (Re-
gional Hospitals of Locarno and Bellinzona). Every patient 
had to be cardiopulmonary compensated showing a stable 
weight at least in the 4 days before inclusion. We excluded 
patients with evidence ofunstable renal fonction in the last 
two weeks (serum creatinine excursions >20 µmol/!), be-
fore inclusion. 
To minimise bias, starting on kick-off day, ail patients 
meeting the selection criteria were asked to participate in 
the study and every patient from whom an informed con-
sent was obtained was recruited. 
On the inclusion day, blood samples were obtained from 
each patient to determine serum creatinine, cystatin C and 
beta-trace protein additionally bioimpedance was assessed. 
On the same day the glomerular filtration rate (GFR) was 
measured using a single bolus inulin clearance [36]. 
Blood samples were rapidly (waiting time <15 minutes) 
centrifuged for 10 minutes ( 1,500 RPM) in the local labor-
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atory. Plasma and serum were extracted and frozen at re-
spectively -80 and -20 °C and then sent to the "Central 
Chemical and Immunology Laboratory of the Public Hos-
pital Network of Bellinzona" to determine the serum creat-
inine, Cystatin C and beta-trace protein and to the "Neph-
rology Research Laboratory of the Lausanne University 
Hospital" to detennine the plasma inulin. 
Laboratory assessments for serum creatinine, cystatin 
C and beta-trace protein and for plasma inulin 
To obtain the serum creatinine value, a modified IDMS cal-
ibrated kinetic Jaffé reaction on a Hitachi 912 photometer 
was used. Serum cystatin C and beta trace-protein levels 
were analysed with the Siemens method using the Behring 
Nephelometer II. 
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Figure 1 
Box Plot showing the absolute error ln estimating GFR (lnulin 
clearence as the gold standard). CYSA, BTPA, CKCA, MDRDA, 
ALMA = absolute error in estimating the GFR using algorithms 
based respectively on Cystatin C; Beta-trace protein, creatinine and 
anthropometric values (Cockcroft); creatinine and anthropometric 
values (MDRD), creatinine, anthropometric values and 
appendicular lean mass (approximating muscle mass) measured by 
bioimpedance. 
Figure 2 
Scatterplots comparing the estimations obtained with the tested 
algorithms to the GFR measured by inulin; the diagonal line 
indicates the equality. A Passing and Bablok analysis shows the 
trend of the distribution and its 95% confidence intervals. 
GFR CYS = GFR estlmated by Cystatin C; GFR BTP = GFR 
estimated by Beta Trace Protein; GFR ALM = GFR estimated by 
Appendicular Lean Mass and creatinine. GFR CKC= GFR 
estimated by Cockcroft's algorithm. GFR MDRD = GFR estimated 
by MDRD (Modification of Diet in Rena! Disease) algorithm. 
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Plasma inulin was determined using a spectrophotometer 
(microadaptation of an anthrone procedure on a Technicon 
Autoanalyser [37]). 
Inulin clearance 
Inulin clearance has been used as the gold standard for 
the determination of GFR [39, 40]. Considering (!.) the 
known good correlation between the clearance values ob-
tained with a constant infusion of inulin and with a single 
shot method respectively and (2.) the simplicity of the short 
infusion strategy, the latter was used to determine the GFR 
[35, 36]. 
Two timed blood samples after the bolus injection of inulin 
could have been enough to ca!culate the GFR [36]; we de-
cided however to increase the number of blood samples to 
4 in order to set up a better disappearance curve and to es-
timate the inulin clearance ( one-compartment mode!) thrice 
for every patient according to the following formula. 
GFR Inulin = (ln C,,_1 - ln C,,)l(t,,_1 - 111) 
(C = inulin concentration [mg/!]; t = time [min]) 
Concerning the inulin administration; on the study day, at 
lime 0, a bolus of 12.5 ml oflnutest® (a solution contain-
ing 25% inulin) was administered intravenously over 10 
minutes. Altogether five blood samples were obtained; the 
first one prior to inulin administration and then at 90, 180, 
270 and 360 minutes. 
GFR and creatinine clearance estimation 
To estimate creatinine clearance and GFR, the algorithms 
of Cockcroft (CCL CKC) and Levey (GFR MDRD) based 
on serum creatinine and anthropometric values, Larsson 
based on cystatin C (GFR CYS), White based on serum 
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Figure 3 
ROC Curves plotting the sensitivity against 1 minus the specificity 
of the selected algorithms in predictlng an inulin clearance <30 ml/ 
min. 
CYS = GFR estimated by Cystatin C; BTP = GFR estimated by 
Beta Trace Protein; ALM = GFR estimated by Appendicular Lean 
Mass and creatinine. CKC= GFR estimated by Cockcroft's 
algorithm. MDRD = GFR estimated by MDRD (Modification of Diet 
in Renal Disease) algorithm. The ideal test would have an AUC of 
1, whereas a random guess would have an AUC of 0.5. 
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creatinine and beta-trace protein (GFR BTP) and MacDon-
ald based on serum creatinine, anthropometric values and 
the appendicular Jean mass obtained by bio-impedance 
(proportional to muscular mass) (GFR ALM) were used 
(table 1 ). 
Cystatin C and Beta Trace Protein 
Cystatin C is an endogenous, 13 kilo-Dalton protein, gen-
erated at a relatively constant rate, freely filtered by the 
glomeruli and reabsorbed and catabolised by the tubular 
epithelial cells [12, 13]. 
Similarly, Beta Trace Protein is a low molecular weight 
glycoprotein, primarily isolated as prostaglandin D2 syn-
thase, in its turn filtered by the glomeruli and with minimal 
extra-renal elimination [ 19, 20]. 
Predicting appendicular lean mass by bioimpedance 
The appendicular lean mass was estimated by bioimped-
ance; a commonly used method for estimating body com-
position based on the study of the passive electrical proper-
ties of the biological tissues. Bio-impedance allows estim-
ating the relative volumes of different tissues or fluids in 
the body as total body water, appendicular Jean mass (ap-
proximating the muscle mass) and fat body weight. 
The efficacy and the reproducibility of the bioimpedance 
in estimating the body composition has been evaluated and 
judged favorably in many studies [38-40]. 
To perform the measurements electrodes were put on the 
dorsal surfaces of the ipsilateral wrist and ankle (on the 
metacarpal- and metatarsal phalangealjoint of the hand and 
foot) and a BIA 101 device (Akern, Florence, Italy) was 
used. Then, on the basis of the resulting resistance (Rz) and 
reactance (Xe), using the Bodygram® software, the appen-
dicular lean mass (ALM) was calculated. 
Statistical and data analysis 
Statistical and data analysis were performed using the 
SPSS 20.0 and the Analyse-it 2.26 statistical software 
packages. Considering that the absolute error in predicting 
GFR is not normally distributed we decided to analyse the 
significance using a Friedman Test. In ail cases a p ::;0.05 
was considered statistically significant. Distributions were 
graphically depicted using box-plots and scatterplots. 
The quality of the measurements of the inulin clearances 
was assessed analysing the intra-patient dispersion of the 
GFR values calculated as the median of the difference 
between the extremes. 
To compare the accuracy of the selected prediction al-
gorithms we used: a Eland and Altman analysis in which 
the error is plotted against the mean of measured and es-
timated GFR [ 41 ], a Passing and Bablok analysis depicting 
graphycally the trend and 95% confidence intervals of the 
distribution and receiver operating characteristic curves 
(ROC) which give a graphical display of sensitivity and 
specificity of the test. In ROC curves the sensitivity is plot-
ted versus 1 - specificity, with each point of the curve rep-
resenting a different cut-offlevel. The area under the curve 
(AUC) describes the test overall performance; to facilitate 
comparisons between individual variables the value was 
given with the 95% confidence interval. 
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Ethical approval was obtained from the local Ethics Com-
mittee (Comitato Etico Cantonale, Bellinzona), and all par-
ticipants gave written informed consent prior to enrolment. 
Results 
From the 70 recruited patients, one was excluded for in-
complete blood samples. 
The demographic and clinical characteristics of the study 
group are presented in table 2. As a comparison, the mean 
age and eGFR (MORD) of the totality of the patients ad-
mitted to the internai medicine wards of the two hospitals 
in the study year (N = 5,676) was (median and interquartile 
range) 76 (66-84) years and 57 (38-81) ml/min respect-
ively. Patients with chronic kidney disease stage III-IV 
represented 52.9% of the entire population. 
1: I ,: ···~:~~;;:: ;. 
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Figure 4 
Bland and Altman analysis. ln this analysis the differenœs between 
the gold standard and the selected prediction algorithm, are plotted 
against the mean of measured and calculated GFR for each 
indivldual patient. 
GFR CYS = GFR estimated by Cystatin C; GFR BTP = GFR 
estimated by Beta Trace Protein; GFR ALM = GFR estimated by 
Appendicular Lean Mass and creatinine. GFR CKC= GFR 
estimated by Cockcroft's algorithm. GFR MORD= GFR estlmated 
by MORD (Modification of Die! in Rena! Disease) algorithm. 
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The GFR measured with inulin and calculated with the se-
lected algorithms and the absolute error in performing the 
estimation (median and mean values to allow a quantitative 
comparison) are listed in table 3. The reliability of the in-
ulin clearance was assessed analysing the intra-patient ab-
solute difference between the extremes of the three indi-
vidual determinations (median, 25% and 75% interquartile 
ranges which were: 8.2, 3.6 and 13.6 ml/min respectively). 
Ail selected algorithms significantly overestimate GFR in 
our group of patients (p <0.001). 
The absolute error in estimating GFR is depicted graphic-
ally in figure 1. The difference among the median values 
of the selected algorithms was found to be significant (p 
<0.001). The estimations obtained on the basis of cystatin 
C were characterised by the lowest median and mean error 
(table 3), white those obtained with the McDonald al-
gorithm were the worst. Outliers 45 and 46 were character-
ised by a large body weight and estimated muscular mass 
(118 and 98, and 40 and 35 kg respectively). 
The distribution of the values obtained estimating GFR 
with the 5 tested algorithms, compared to the reference 
method (inulin clearance) is depicted graphically using 
scatterplots in figure 2. A Passing and Bablok analysis 
shows the trend of the distribution and its 95% confidence 
intervals compared to the identity line. 
The ROC curves comparing sensitivity and specificity of 
the tested algorithms in predicting an inulin clearance <30 
ml/min are depicted in figure 3. The area under the curves 
and the 95% confidence intervals were respectively: CKC 
0.68 (0.55-0.81), MORD 0.76 (0.64-0.87), Cystatin C 0.82 
(0.72-0.92), BTP 0.75 (0.63--0.87), ALM 0.65 (0.52-0.78). 
The Bland and Altman analysis is shown in figure 4. 
The percentage of patients wrongly attributed on the basis 
of the selected prediction algorithm, to a lower or a higher 
CKD stage is summarised in table 4. GFR CYS, inducing 
Jess class changes compared to the other algorithms, ob-
tained the better score followed in order by GFR CKC, 
GFR MORD, GFR BTP and GFR ALM. 
Table 1: Selected estimation algorithms. Formula used to estimate the Creatinine Clearance and the GFR respectively. 
GFR or CCI (ml/min) Algorithm 
CCLCKC (140- age [year]) x weight [kg]/ (creatinine [µmolli] x 72) x (0.85 iffemale) 
GFRMDRD 175 x (creatinine [µmol/JJr1·154 x (age [yearJr0·203 x (0.742 iffemale) 
GFRCYS 77.239 x Cystatin c (mg11r1·2523 
GFRBTP 167.8 x BTP [mg/l]--0.759 x creatinine [µmolfil-0·204 x (0.871 iffemale) 
GFRALM 101.ooa 1.014 x LOG10 (creatinine [µmol~]/ 88) + 0.01644 x ALM [kg)+ 0.07108 x" weight (Kg) 
CCL CKC = creatinine clearance estimated by the Cockcroft algorithm; GFR MORD= GFR estimated by the MORD (Modification of Diet in Renal Disease) algorithm; GFR 
CYS= GFR estimated on the basis of the cystatin C value; GFR BTP = GFR estimated on the basis of the creatinine and the beta-trace protein value; GFR ALM = GFR 
estimated on the basis of the creatinine and the appendicular lean mass. 
Table 2: Ciinical characteristics of the studied population (n = 69). 
Median (25-75% interquartile range) Mean± SD 
Age (years) 80 (73-83) 78 ± 7 
Weight (kg) 74.7 (67.0-85.6) 77.3± 15.2 
BMI (kgim'J 26.0 (23.3-30.0) 27.3 ± 5.2 
ALM (kg) 19.1 (14.9-22.3) 19.1±6.1 
Creatinine (µmolli) 126 (100-149) 134 ± 62 
Cystatin C (mg/I) 1.45 (1.19-1.90) 1.71 ±0.87 
Beta-trace protein (mg/I) 1.17 (0.99-1.53) 1.34 ± 0.64 
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Discussion 
In this study, we compared 5 different equations designed 
to estimate kidney function, based on serum creatinine 
(Cockcroft [3] and MORD [5]), cystatin C (Larsson [U]), 
creatinine combined with beta-trace protein (White [20]), 
and creatinine adjusted for muscle mass obtained by bio-
electrical impedance analysis (MacDonald [30]), respect-
ively. Inulin clearance measured by the single shot method 
was taken as the gold standard [34-36]. The population un-
der study, entirely of European Caucasian ethnicity, was 
chosen amongst the inpatients admitted to the internai 
medicine wards oftwo secondary care hospitals in southem 
Switzerland. The only criteria for their selection were, an 
age of>70 years and a chronic compromised kidney func-
tion based on MORD eGFR (CKD stages III-IV). 
As suggested by previous studies [2, 32], ail tested equa-
tions are on average significantly overestimating kidney 
function (+ 11.8 ml/min Cockcroft, + 12.4 ml/min cystatin 
C, +14.l ml/min MORD, +19.5 ml/min beta-trace protein, 
+32.9 ml/min creatinine and muscle mass). In this respect, 
a considerable number of patients would have changed 
their KDOQI CKD severity classification by adjusting 
GFR for the results of inulin clearance: 49% in the estim-
ation based on cystatin C, 56% by MORD, 52% by Cock-
croft, 65% by beta-trace protein and 75% by creatinine and 
muscle mass (table 4). 
The inaccuracy of equations in this inpatient population 
with extreme characteristics related to old age and poly-
morbidity is not surprising and has been previously repor-
ted [32]. 
However, considering how some criticalities attributed to 
creatinine relate to the difficulty in estimating muscle mass, 
we would have expected a better result from the MacDon-
ald formula, obtained by adjusting creatinine for body com-
position data measured by bioelectrical impedance ana-
lysis. Value dispersion was quite similar to that of other 
equations or actually even worse (see error dispersion in 
Swiss Med Wkly. 2012;142:w13708 
box plots, ROC curves and Bland-Altman analysis; figures 
1, 3 and 4 respectively). We therefore had to conclude that 
the determination of muscle mass by bioelectrical imped-
ance analysis did not result in any significant added contri-
bution in estimating GFR in the population under study. 
However, taking into consideration the sound theoretical 
context in favour of the definition and use of such an equa-
tion, we wondered why the MacDonald formula proved to 
be imprecise. The small size of the population used to de-
termine it, the Jack of external validation [30], the extreme 
characteristics of the group which we tested, the possible 
Joss of precision in the analysis of body composition in 
polymorbid elderly patients [42] and the use of a differ-
ent software to determine body composition, could ail have 
contributed to increased error dispersion. 
The use ofbioelectrical impedance analysis to reduce error 
in creatinine-related GFR estimation, still retains a theoret-
ical attractiveness, and will have to be reassessed in studies 
based on a wider population representative of the in-hospit-
al one, for which the interest in using a predictive equation 
is greater. 
The second surprise was to observe that the MORD for-
mula did not offer significant advantages compared to 
Cockcroft and seems to be less effective when compared 
with the Larsson one. 
The relative imprecision of the MORD formula might be 
related to the selected population (American in MORD and 
European in Cockcroft and Larsson) or, once again, to the 
clinical characteristics of the population such as advanced 
age and polymorbidities of the group in which we per-
formed the evaluation. 
The results of the present study once again suggest that the 
equations obtained from large clinical studies thus show 
fragility in the extremes - in this case, advanced age and 
polymorbidities [38]. This is particularly relevant as the 
group selected for the study (CKD stages III-IV based on 
Table 3: Measured versus estimated GFR. GFR measured with inulin and calculated with the selected algorithms and absolute errer in performing the estimation. Data are 
given using non-parametric and parametric values to allow a quantitative comparison; mean and SD values of the absolute errer correlate with accuracy and preclsion 
respectively. 
Median (25-75% interquartile Mean± SD Median error (25-75% interquartile Mean error ± SD 
range) ml/min ml/min range) ml/min ml/min 
GFR lnulin 30.9 (22.0-43.3) 34.9 ± 20.0 
GFRCKC 45.1 (34.6-55.3) 46.7 ± 18.5 14.3 (5.55-23.2) 11.8 ± 19.2 
GFRCYS 45.9 (31.9-59.4) 47.2 ± 23.0 12.8 (4.50-25.3) 12.4 ± 20.6 
GFR BTP 54.2 (42.2-62.4) 54.4 ± 18.2 17.6 (11.5-31.5) 19.5 ± 17.7 
GFR MORD 47.9 (39.5-60.1) 49.0 ± 15.9 16.3 (6.4-27.5) 14.1±19.8 
GFRALM 66.0 (46.3-77.7) 32.9 ± 27.2 32.2 (13.9-45.4) 32.9 ± 27.2 
GFR CYS = GFR estimated by Cystatin C; GFR BTP = GFR estimated by Beta Trace Protein; GFR ALM = GFR estimated by Appendicular Lean Mass and creatinine. 
GFR CKC - GFR estimated by Cockcroft's algorithm. GFR MORD= GFR estimated by MORD (Modification of Diet in Renal Disease) algorithm. 
Table 4: Percentage of KDOQI CKD class change [25] obtained correcting the results of the estimations with the gold standard (GFR lnulin). 
KDOQI Class change GFR BTP GFR MORD GFRALM GRFR CYS GFR CKC 
Total class change% 65.3 56.5 75.5 49.3 52.3 
+1 class 50.7 46.4 37.7 39.1 37.7 
-1 class 1.5 7.2 0 1.5 5.8 
+2 classes 11.6 2.9 31.9 7.2 5.8 
-2 classes 1.5 0 1.5 1.5 1.5 
± >2 classes 0 0 4.4 0 1.5 
GFR CYS = GFR estimated by Cystatin c; GFR BTP = GFR estimated by Beta Trace Protein; GFR ALM = GFR estimated by Appendicular Lean Mass and creatinine. 
GFR CKC- GFR estimated by Cockcroft's algorithm. GFR MORD= GFR estimated by MORD (Modification of Diet in Renal Disease) algorithm. 
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eGFR MDRD) accounts for 53% of the patients admitted 
to the internai medicine wards of our hospitals. 
Beta-trace protein does not seem to offer specific advant-
ages against creatinine and cystatin C; while the White 
equation is the only one that does not generate outliers. Un-
fortunately this latter shows a greater error dispersion in 
GFR estimation than Cockcroft, Larsson and MDRD. 
What are we supposed to do in the face of such a large 
margin of error? Assuming that the results were not gen-
erated by a bias related to the small group of patients ana-
lysed or to the single shot method used to measure in-
ulin clearance (see intra-patient dispersion of the GFR de-
termination in the results section); ail the equations tested 
seem to be prone to considerably overestimate GFR. While 
we can imagine using the ones offering the best perform-
ance, we are not safe from either, the risk of intoxicating 
patients with medications eliminated mainly by the renal 
route characterised by a narrow therapeutic margin (e.g., 
some chemotherapics and antibiotics), and in a smaller 
subgroup, the risk of being, on the contrary, below the 
therapeutic range. Considering the relevance of the topic 
and the amount of in-hospital patients matching the se-
lection criteria of the study, further investigation aimed to 
confirm and more extensively characterising patients with 
large GFR estimation errors, should be performed. 
Therefore, it is of the utmost importance to closely monitor 
the onset of any toxicity signs; whenever serum concentra-
tions of a medication used cannot be measured and to be 
ready to adjust its dose or, when necessary, to replace the 
drug with an alternative one. One important issue in elderly 
patients is the correction ofGFR to a standard body surface 
area (1.73 m2) as for example in the MDRD formula. Pa-
tients in the extremes ofweight do often not have a normal 
body surface area and in that case drug overdosing may oc-
cur as well. In this respect the Cockcroft formula, consid-
ering also the weight, could be the safcst. 
In conclusion, the Cockcroft, Larsson, MDRD, White and 
MacDonald equations are significantly overestimating kid-
ney function in our CKD stage III-IV inpatient population 
(average overestimation ranging from 11.4 to 32.9 ml/min; 
the extremes being Cockcroft and Macdonald respect-
ively ). These results are important because the selected 
population represents at least half of all patients admitted 
in an internai medicine ward. 
The best performance was obtained with the Larsson equa-
tion, based on cystatin C. The measurement by bioelectric-
al impedance analysis of muscle mass, introduced with cre-
atinine in the MacDonald formula, does not allow more 
accurate results to be obtained, at least in our population of 
patients. 
Clinicians must therefore use estimated GFR with 
prudence, being ready to discontinue medications with nar-
row therapeutic margins eliminated by the renal route in 
all cases ofsuspected toxicity. New studies designed to im-
prove predictive equations to be used in elderly in-hospital 
populations should be conducted. 
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Scatterplots comparing the estimations obtained with the tested algorithms to the GFR measured by inulin; the diagonal line indicates the 
equality. A Passing and Bablok analysis shows the trend of the distribution and its 95% confidence intervals. 
GFR CYS = GFR estimated by Cystatin C; GFR BTP = GFR estimated by Beta Trace Protein; GFR ALM = GFR estimated by Appendicular 
Lean Mass and creatinine. GFR CKC= GFR estimated by Cockcroft's algorithm. GFR MORD= GFR estimated by MORD (Modification of Diet in 
Renal Disease) algorithm. 
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ROC Curves plotting the sensitivity against 1 minus the specificity of the selected algorithms in predicling an inulin clearance <30 ml/min. 
CYS = GFR estimated by Cystalin C; BTP = GFR estimated by Beta Trace Protein; ALM = GFR eslimated by Appendicular Lean Mass and 
creatinine. CKC= GFR estimated by Cockcroft's algorithm. MORD = GFR estimated by MORD (Modification of Diet in Renal Disease) algorithm. 
The ideal test would have an AUC of 1, whereas a random guess would have an AUC of 0.5. 
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Bland and Altman analysis. ln this analysis the differences between the gold standard and the selected prediction algorithm, are plotted against 
the mean of measured and calculated GFR for each individual patient. 
GFR CYS = GFR estimated by Cystatin C; GFR BTP = GFR estimated by Beta Trace Protein; GFR ALM = GFR estimated by Appendicular 
Lean Mass and creatinine. GFR CKC= GFR estimated by Cockcroft's algorithm. GFR MDRD = GFR estimated by MDRD (Modification of Diet in 
Renal Disease) algorithm. 
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